Self-Assembled Nanoparticles from Phenolic Derivatives for Cancer Therapy

Yunlu Dai, Junling Guo, Ting Yi Wang, Yi Ju, Andrew J. Mitchell, Thomas Bonnard, Jiwei Cui, Joseph J. Richardson, Christoph E. Hagemeyer, Karen Alt, Frank Caruso

Research output: Contribution to journalArticleResearchpeer-review

Abstract

Therapeutic nanoparticles hold clinical promise for cancer treatment by avoiding limitations of conventional pharmaceuticals. Herein, a facile and rapid method is introduced to assemble poly(ethylene glycol) (PEG)-modified Pt prodrug nanocomplexes through metal-polyphenol complexation and combined with emulsification, which results in ≈100 nm diameter nanoparticles (PtP NPs) that exhibit high drug loading (0.15 fg Pt per nanoparticle) and low fouling properties. The PtP NPs are characterized for potential use as cancer therapeutics. Mass cytometry is used to quantify uptake of the nanoparticles and the drug concentration in individual cells in vitro. The PtP NPs have long circulation times, with an elimination half-life of ≈18 h in healthy mice. The in vivo antitumor activity of the PtP NPs is systematically investigated in a human prostate cancer xenograft mouse model. Mice treated with the PtP NPs demonstrate four times better inhibition of tumor growth than either free prodrug or cisplatin. This study presents a promising strategy to prepare therapeutic nanoparticles for biomedical applications.

Original languageEnglish
Article number1700467
Number of pages7
JournalAdvanced Healthcare Materials
Volume6
Issue number16
DOIs
Publication statusPublished - 23 Aug 2017

Keywords

  • Nanoparticles
  • Platinum prodrugs
  • Polyphenols
  • Self-assembly
  • Tumor therapy

Cite this

Dai, Yunlu ; Guo, Junling ; Wang, Ting Yi ; Ju, Yi ; Mitchell, Andrew J. ; Bonnard, Thomas ; Cui, Jiwei ; Richardson, Joseph J. ; Hagemeyer, Christoph E. ; Alt, Karen ; Caruso, Frank. / Self-Assembled Nanoparticles from Phenolic Derivatives for Cancer Therapy. In: Advanced Healthcare Materials. 2017 ; Vol. 6, No. 16.
@article{6ff586c7742347bea8046f0e86d57a27,
title = "Self-Assembled Nanoparticles from Phenolic Derivatives for Cancer Therapy",
abstract = "Therapeutic nanoparticles hold clinical promise for cancer treatment by avoiding limitations of conventional pharmaceuticals. Herein, a facile and rapid method is introduced to assemble poly(ethylene glycol) (PEG)-modified Pt prodrug nanocomplexes through metal-polyphenol complexation and combined with emulsification, which results in ≈100 nm diameter nanoparticles (PtP NPs) that exhibit high drug loading (0.15 fg Pt per nanoparticle) and low fouling properties. The PtP NPs are characterized for potential use as cancer therapeutics. Mass cytometry is used to quantify uptake of the nanoparticles and the drug concentration in individual cells in vitro. The PtP NPs have long circulation times, with an elimination half-life of ≈18 h in healthy mice. The in vivo antitumor activity of the PtP NPs is systematically investigated in a human prostate cancer xenograft mouse model. Mice treated with the PtP NPs demonstrate four times better inhibition of tumor growth than either free prodrug or cisplatin. This study presents a promising strategy to prepare therapeutic nanoparticles for biomedical applications.",
keywords = "Nanoparticles, Platinum prodrugs, Polyphenols, Self-assembly, Tumor therapy",
author = "Yunlu Dai and Junling Guo and Wang, {Ting Yi} and Yi Ju and Mitchell, {Andrew J.} and Thomas Bonnard and Jiwei Cui and Richardson, {Joseph J.} and Hagemeyer, {Christoph E.} and Karen Alt and Frank Caruso",
year = "2017",
month = "8",
day = "23",
doi = "10.1002/adhm.201700467",
language = "English",
volume = "6",
journal = "Advanced Healthcare Materials",
issn = "2192-2640",
publisher = "Wiley-Blackwell",
number = "16",

}

Dai, Y, Guo, J, Wang, TY, Ju, Y, Mitchell, AJ, Bonnard, T, Cui, J, Richardson, JJ, Hagemeyer, CE, Alt, K & Caruso, F 2017, 'Self-Assembled Nanoparticles from Phenolic Derivatives for Cancer Therapy' Advanced Healthcare Materials, vol. 6, no. 16, 1700467. https://doi.org/10.1002/adhm.201700467

Self-Assembled Nanoparticles from Phenolic Derivatives for Cancer Therapy. / Dai, Yunlu; Guo, Junling; Wang, Ting Yi; Ju, Yi; Mitchell, Andrew J.; Bonnard, Thomas; Cui, Jiwei; Richardson, Joseph J.; Hagemeyer, Christoph E.; Alt, Karen; Caruso, Frank.

In: Advanced Healthcare Materials, Vol. 6, No. 16, 1700467, 23.08.2017.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Self-Assembled Nanoparticles from Phenolic Derivatives for Cancer Therapy

AU - Dai, Yunlu

AU - Guo, Junling

AU - Wang, Ting Yi

AU - Ju, Yi

AU - Mitchell, Andrew J.

AU - Bonnard, Thomas

AU - Cui, Jiwei

AU - Richardson, Joseph J.

AU - Hagemeyer, Christoph E.

AU - Alt, Karen

AU - Caruso, Frank

PY - 2017/8/23

Y1 - 2017/8/23

N2 - Therapeutic nanoparticles hold clinical promise for cancer treatment by avoiding limitations of conventional pharmaceuticals. Herein, a facile and rapid method is introduced to assemble poly(ethylene glycol) (PEG)-modified Pt prodrug nanocomplexes through metal-polyphenol complexation and combined with emulsification, which results in ≈100 nm diameter nanoparticles (PtP NPs) that exhibit high drug loading (0.15 fg Pt per nanoparticle) and low fouling properties. The PtP NPs are characterized for potential use as cancer therapeutics. Mass cytometry is used to quantify uptake of the nanoparticles and the drug concentration in individual cells in vitro. The PtP NPs have long circulation times, with an elimination half-life of ≈18 h in healthy mice. The in vivo antitumor activity of the PtP NPs is systematically investigated in a human prostate cancer xenograft mouse model. Mice treated with the PtP NPs demonstrate four times better inhibition of tumor growth than either free prodrug or cisplatin. This study presents a promising strategy to prepare therapeutic nanoparticles for biomedical applications.

AB - Therapeutic nanoparticles hold clinical promise for cancer treatment by avoiding limitations of conventional pharmaceuticals. Herein, a facile and rapid method is introduced to assemble poly(ethylene glycol) (PEG)-modified Pt prodrug nanocomplexes through metal-polyphenol complexation and combined with emulsification, which results in ≈100 nm diameter nanoparticles (PtP NPs) that exhibit high drug loading (0.15 fg Pt per nanoparticle) and low fouling properties. The PtP NPs are characterized for potential use as cancer therapeutics. Mass cytometry is used to quantify uptake of the nanoparticles and the drug concentration in individual cells in vitro. The PtP NPs have long circulation times, with an elimination half-life of ≈18 h in healthy mice. The in vivo antitumor activity of the PtP NPs is systematically investigated in a human prostate cancer xenograft mouse model. Mice treated with the PtP NPs demonstrate four times better inhibition of tumor growth than either free prodrug or cisplatin. This study presents a promising strategy to prepare therapeutic nanoparticles for biomedical applications.

KW - Nanoparticles

KW - Platinum prodrugs

KW - Polyphenols

KW - Self-assembly

KW - Tumor therapy

UR - http://www.scopus.com/inward/record.url?scp=85019213004&partnerID=8YFLogxK

U2 - 10.1002/adhm.201700467

DO - 10.1002/adhm.201700467

M3 - Article

VL - 6

JO - Advanced Healthcare Materials

JF - Advanced Healthcare Materials

SN - 2192-2640

IS - 16

M1 - 1700467

ER -